Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed o6-methylguanine-DNA-methyltransferase (MGMT) Negative Glioblastoma Multiforme (GBM)
Condition: Glioblastoma Multiforme of Brain Interventions: Biological: TVI-Brain-1; Procedure: Standard of Care; Radiation: Radiotherapy; Drug: Temozolomide Sponsors: TVAX Biomedical; FDA Office of Orphan Products Development Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 13, 2023 Category: Research Source Type: clinical trials
Glutamate Inhibitors in Glioblastoma
Condition: Glioblastoma Interventions: Drug: Gabapentin; Drug: Sulfasalazine; Drug: Memantine; Drug: Temozolomide; Radiation: Radiotherapy Sponsors: University of Zurich; Swiss National Science Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Condition: Glioblastoma Interventions: Biological: Autologous genetically modified gamma-delta T cells; Biological: Allogeneic genetically modified gamma-delta T cells Sponsor: In8bio Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials
LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas
Condition: Recurrent Glioblastoma Interventions: Procedure: Laser interstitial thermal therapy; Drug: Temozolomide Sponsor: Beijing Tiantan Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials
Glutamate Inhibitors in Glioblastoma
Condition: Glioblastoma Interventions: Drug: Gabapentin; Drug: Sulfasalazine; Drug: Memantine; Drug: Temozolomide; Radiation: Radiotherapy Sponsors: University of Zurich; Swiss National Science Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Condition: Glioblastoma Interventions: Biological: Autologous genetically modified gamma-delta T cells; Biological: Allogeneic genetically modified gamma-delta T cells Sponsor: In8bio Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials
LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas
Condition: Recurrent Glioblastoma Interventions: Procedure: Laser interstitial thermal therapy; Drug: Temozolomide Sponsor: Beijing Tiantan Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials
Glutamate Inhibitors in Glioblastoma
Condition: Glioblastoma Interventions: Drug: Gabapentin; Drug: Sulfasalazine; Drug: Memantine; Drug: Temozolomide; Radiation: Radiotherapy Sponsors: University of Zurich; Swiss National Science Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Condition: Glioblastoma Interventions: Biological: Autologous genetically modified gamma-delta T cells; Biological: Allogeneic genetically modified gamma-delta T cells Sponsor: In8bio Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials
LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas
Condition: Recurrent Glioblastoma Interventions: Procedure: Laser interstitial thermal therapy; Drug: Temozolomide Sponsor: Beijing Tiantan Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials
Glutamate Inhibitors in Glioblastoma
Condition: Glioblastoma Interventions: Drug: Gabapentin; Drug: Sulfasalazine; Drug: Memantine; Drug: Temozolomide; Radiation: Radiotherapy Sponsors: University of Zurich; Swiss National Science Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials